| EFFICACY, PHARMACOKINETICS, SAFETY AND IMMUNOGENICITY OF THE BIOSIMILAR HS016 IN COMPARISON WITH ADALIMUMAB IN CHINESE PATIENTS WITH ANKYLOSING SPONDYLITIS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 3 TRIAL | |
| Su, Jinmei; Li Mengtao; Zeng, Xiaofeng | |
| 2019 | |
| 会议名称 | ANNALS OF THE RHEUMATIC DISEASES |
| 会议日期 | 2019-06-01 |
| 页码 | 894-894 |
| 收录类别 | CPCI-S |
| URL标识 | 查看原文 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6337272 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Su, Jinmei,Li Mengtao,Zeng, Xiaofeng. EFFICACY, PHARMACOKINETICS, SAFETY AND IMMUNOGENICITY OF THE BIOSIMILAR HS016 IN COMPARISON WITH ADALIMUMAB IN CHINESE PATIENTS WITH ANKYLOSING SPONDYLITIS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 3 TRIAL[C]. 见:ANNALS OF THE RHEUMATIC DISEASES. 2019-06-01. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论